Keeping Track: First Gliomas Imaging Agent Wins Approval; Amgen Hopes New Repatha Data Boosts Prospects
Executive Summary
The latest drug development news and US FDA highlights from our Performance Tracker.
You may also be interested in...
Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m
Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.
Praluent Injunction Goes Unmentioned At PCSK9 Patent Case Appeal
Three-judge US federal appellate panel focuses on evidentiary rulings and patent validity in the dispute between Repatha marketer Amgen and Sanofi/Regeneron; lower court’s permanent injunction barring sales of Praluent did not come up at oral arguments.
Keeping Track: Oncology Announcements, Priority Review Vouchers Continue To Pile Up
The latest drug development news and US FDA highlights from our Performance Tracker.